Mydecine Innovations Group (OTCMKTS:MYCOF) is a clinical‐stage biotechnology company dedicated to the research, development and commercialization of novel therapeutics derived from psychedelic and plant-based compounds. The company’s primary focus lies in advancing a pipeline of next‐generation product candidates targeting mental health disorders, addiction and other neurological conditions. Mydecine holds a portfolio of intellectual property that encompasses proprietary chemical entities, drug delivery systems and manufacturing processes for molecules such as 5-MeO-DMT analogs, ibogaine-derived compounds and psilocybin formulations.
Headquartered in Denver, Colorado, with additional research and manufacturing facilities in Vancouver, Canada, Mydecine operates a vertically integrated business model. Through strategic acquisitions—including a cGMP laboratory and an established pipeline of ibogaine analogs—the company has bolstered its capacity to conduct preclinical studies and produce active pharmaceutical ingredients at scale. Its contract development and manufacturing (CDMO) arm supports both internal programs and external partners seeking to advance psychedelic compounds under regulatory guidelines.
The management team at Mydecine Innovations Group brings together seasoned executives from the pharmaceutical and biotechnology sectors, with collective expertise in clinical development, regulatory affairs and commercial strategy. The company is actively preparing investigational new drug (IND) submissions for lead candidates while exploring additional psychedelic and botanical molecules for indications such as post-traumatic stress disorder (PTSD) and substance use disorders. Collaborative agreements with academic research centers enhance its ability to translate early-stage findings into clinical programs.
Since its founding, Mydecine Innovations Group has pursued growth through research innovation, strategic acquisitions and the development of protected intellectual property. Serving both as a drug developer and a CDMO provider, the company is positioned to meet evolving demand in the emerging field of psychedelic medicine. With a focus on regulatory alignment and commercial readiness, Mydecine continues to advance its therapies toward clinical milestones in North America and beyond.
AI Generated. May Contain Errors.
